Factors associated with immunotherapy use among newly diagnosed cancer patients

Medical Care

Volumn 47, Issue 9, 2009, Pages 948-958

  Shih, Ya Chen Tina ^a   Elting, Linda S ^a   Halpern, Michael T ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Cancer; Immunotherapy; Insurance endogeneity; Technology diffusion

Indexed keywords

BEVACIZUMAB; CETUXIMAB; RITUXIMAB; TRASTUZUMAB;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGISTRY; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; METASTASIS; NONHODGKIN LYMPHOMA; RACE DIFFERENCE; UNITED STATES;

AGED; DIFFUSION OF INNOVATION; FEMALE; HUMANS; IMMUNOTHERAPY; INSURANCE, HEALTH; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; REGRESSION ANALYSIS; UNITED STATES;

EID: 69449103702     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31819a5b2b     Document Type: Article

References (55)

1. American Cancer Society. Monoclonal Antibodies. Available at: http://www.cancer.org/docroot/ETO/content/ETO-1-4X-Monoclonal-Antibody-Therapy- Passive-Immunotherapy.asp. Accessed on March 3, 2008.
2. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nature Reviews. Drug Discov. 2007;6:349-356.
3. Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care. 2006;12:S3-16.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
5. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol. 2007;25:611-613. (Pubitemid 350002913)
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345. (Pubitemid 38944402)
8. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319. (Pubitemid 38944397)
9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
10. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005;103:1644-1651.
11. Annemans L, Van Cutsem E, Humblet Y, et al. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan - a Belgian analysis. Acta Clin Belg. 2007;62:419-425. (Pubitemid 351236175)
12. Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma. 2008;49:227-236. (Pubitemid 351200289)
13. Knight C, Hind D, Brewer N, et al. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2004;8:iii, ix-xi, 1-82. (Pubitemid 39585964)
14. Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol. 2005;16:909-914. (Pubitemid 40903916)
15. Poncet B, Bachelot T, Colin C, et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol. 2008;31:363-368.
16. Starling N, Tilden D, White J, et al. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer. 2007;96:206-212. (Pubitemid 46160622)
17. Tappenden P, Jones R, Paisley S, et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer. 2007;43:2487-2494. (Pubitemid 350086932)
18. NCCN clinical practice guidelines in oncology: colon cancer v. 4.2008, National Comprehensive Cancer Network, Inc., 2008. Available at: http://www.nccn.org/professionals/physician-gls/PDF/colon.pdf. accessed December 10, 2008.
19. NCCN clinical practice guidelines in oncology: breast cancer v. 1.2009, National Comprehensive Cancer Network, Inc., 2008. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. accessed December 10, 2008.
20. NCCN clinical practice guidelines in oncology: Non-Hodgkin's lymphoma v. 3.2008, National Comprehensive Cancer Network, Inc., 2008. Available at: http://www.nccn.org/professionals/physician-gls/PDF/nhl.pdf. accessed December 10, 2008.
21. Harlan LC, Greene AL, Clegg LX, et al. Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol. 2005;23:9079-9088.
22. Koroukian SM, Xu F, Dor A, et al. Colorectal cancer screening in the elderly population: disparities by dual Medicare-Medicaid enrollment status. Health Serv Res. 2006;41:2136-2154. (Pubitemid 44760147)
23. Mitchell JM, Meehan KR, Kong J, et al. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. J Clin Oncol. 1997;15:2644-2651. (Pubitemid 27289896)
24. Parker J, Gebretsadik T, Sabogal F, et al. Mammography screening among California Medicare beneficiaries: 1993-1994. Am J Prev Med. 1998;15:198-205.
25. Potosky AL, Breen N, Graubard BI, et al. The association between health care coverage and the use of cancer screening tests. Results from the 1992 National Health Interview Survey. Med Care. 1998;36:257-270.
26. Richardson LC, Tian L, Voti L, et al. The roles of teaching hospitals, insurance status, and race/ethnicity in receipt of adjuvant therapy for regional-stage breast cancer in Florida. Am J Public Health. 2006;96:160-166. (Pubitemid 43042848)
27. Roetzheim RG, Gonzalez EC, Ferrante JM, et al. Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer. 2000;89:2202-2213.
28. Roetzheim RG, Pal N, Gonzalez EC, et al. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health. 2000;90:1746-1754. (Pubitemid 30812731)
29. Voti L, Richardson LC, Reis I, et al. The effect of race/ethnicity and insurance in the administration of standard therapy for local breast cancer in Florida. Breast Cancer Res Treat. 2006;95:89-95. (Pubitemid 43228085)
30. Ward E, Halpern MT, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58:9-31.
31. Wu X, Chen VW, Andrews PA, et al. Treatment patterns for stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana. J La State Med Soc. 2004;156:255-261.
32. American College of Surgeons: National Cancer Data Base, American College of Surgeons.
33. Halpern MT, Bian J, Ward EM, et al. Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer. 2007;110:403-411. (Pubitemid 47121902)
34. Kennedy BJ, Fremgen AM, Menck HR. The National Cancer Data Base report on Hodgkin's disease for 1985-1989 and 1990-1994. Cancer. 1998;83:1041-1047.
35. Stewart AK, Bland KI, McGinnis LS Jr, et al. Clinical highlights from the National Cancer Data Base, 2000. CA Cancer J Clin. 2000;50:171-183.
36. American College of Surgeons. FORDS: Facility Oncology Registry Data Standards 2007. Available at: http://www.facs.org/cancer/coc/fords/2007/ fordscorrected0707.pdf. Accessed 20 June 2008.
37. Griliches Z. Technology, Education, and Productivity. London,UK: Basil Blackwell; 1988.
38. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27:531-543.
39. Nagle PC, Nicita CA, Gerdes LA, et al. Characteristics of and trends in the late-stage biopharmaceutical pipeline. Am J Manag Care. 2008;14:226-229.
40. Shih YCT. Economic of Cancer in the Elderly Population, Institute of Medicine Cancer in Elderly Population: Workshop Proceeding. Washington, DC: The National Academies Press; 2007.
41. Seo BK, Pisano ED, Kuzimak CM, et al. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol. 2006;13:1211-1218.
42. DeMichele A, Putt M, Zhang Y, et al. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer. 2003;97:2150-2159. (Pubitemid 36444055)
43. Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:151-156. (Pubitemid 40933579)
44. Wang J, Kuo YF, Freeman J, et al. Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected non-small-cell lung cancer. Cancer. 2008;112:382-390.
45. Panageas KS, Elkin EB, Ben-Porat L, et al. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer. 2007;110:1338-1344. (Pubitemid 47435607)
46. Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer. 2000;89:561-573. (Pubitemid 30642535)
47. Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750-2756. (Pubitemid 46630572)
48. Chen AY, Schrag NM, Halpern M, et al. Health insurance and stage at diagnosis of laryngeal cancer: does insurance type predict stage at diagnosis? Arch Otolaryngol-Head Neck Surg. 2007;133:784-790. (Pubitemid 47295759)
49. Chen AY, Schrag NM, Halpern MT, et al. The impact of health insurance status on stage at diagnosis of oropharyngeal cancer. Cancer. 2007;110:395-402. (Pubitemid 47121901)
50. Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9:222-231.
51. Gavin NI, Adams EK, Manning WG, et al. The impact of welfare reform on insurance coverage before pregnancy and the timing of prenatal care initiation. Health Serv Res. 2007;42:4.
52. Ghafoor A, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity. CA Cancer J Clin. 2003;53:342-355.
53. Elmore JG, Nakano CY, Linden HM, et al. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care. 2005;43:141-148. (Pubitemid 40222632)
54. Schwartz KL, Crossley-May H, Vigneau FD, et al. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control. 2003;14:761-766. (Pubitemid 37463889)
55. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007;99:1384-1394. (Pubitemid 351767187)